Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pfizer (PFE)

Pfizer Names Cecile Guegan Chief Financial Officer Effective November 1, 2026

Neutral Impact 4 of 5 leadership

Pfizer's board unanimously elected Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026, after she served as interim CFO since August 16, 2026. The filing sets her base salary at $1,300,000 and her target annual cash incentive at $1,300,000, and it does not report any financial results or change to guidance.

Key points

  • Cecile Guegan appointed CFO and Executive Vice President, effective November 1, 2026; interim CFO since August 16, 2026
  • Annual base salary of $1,300,000
  • Annual target cash incentive of $1,300,000, equal to 100% of base salary
  • She will oversee all corporate finance functions, including audit, treasury, investor relations and tax

The filing

CompanyPfizer (PFE)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:19 PM ET
Accession number0000078003-26-000132

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.